Bernard J. Zovighian - 07 May 2025 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CEO, Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
07 May 2025
Transactions value $
-$318,635
Form type
4
Filing time
09 May 2025, 19:34:11 UTC
Previous filing
06 May 2025
Next filing
13 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zovighian Bernard J CEO, Director ONE EDWARDS WAY, IRVINE Linda J. Park, Attorney-in-Fact 09 May 2025 0001665141

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability -$319K -4.25K -7.43% $74.92 53K 07 May 2025 Direct
transaction EW Common Stock Award $0 +43.6K +82.18% $0.00 96.5K 08 May 2025 Direct F1
transaction EW Common Stock Gift $0 -4.12K -4.27% $0.00 92.4K 08 May 2025 Direct
transaction EW Common Stock Gift $0 +4.12K +31.82% $0.00 17.1K 08 May 2025 By Trust
holding EW Common Stock 3.61K 07 May 2025 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Award $0 +244K $0.00 244K 08 May 2025 Common Stock 244K $74.63 Direct F2
transaction EW Performance Rights Award $0 +43.6K $0.00 43.6K 08 May 2025 Common Stock 43.6K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F2 These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
F3 Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.